UC Davis Health expanded Taiwan partnerships to accelerate biomedical innovation, linking Aggie Square, universities and industry to drive research, commercialization and clinical translation in cell & gene therapy, cancer, medical devices, digital health and AI.
UC Davis, FLANN and partners launched the nine-month Scale-Up Program to help South Korean life-sciences startups enter the U.S. market via Aggie Square, offering clinical collaboration, U.S. market validation, commercialization support, investor access and strategic partnerships.
Through the NSF I-Corps customer discovery program, 2C Bioscience found its beachhead market and a path towards faster commercialization—demonstrating how industry engagement can help turn lab innovations into viable business opportunities.
UC Davis launches Aggie Venture Accelerator, welcoming inaugural cohort of life science startups—SinewUS, Pharm to Food and ThriveSpan Labs—offering mentorship, industry connections and funding to fast-track commercialization.
UC Davis Health awarded more than $390,000 through its STAIR HEALTH proof-of-concept program to support three interdisciplinary research teams advancing promising innovations in cancer imaging, spinal cord injury treatment and breast cancer therapeutics toward commercial and clinical impact.
Born out of cross-disciplinary research at University of California, Davis, startup amplifye is developing enzyme-based technology designed to improve protein absorption and muscle health as growing use of GLP-1 therapies reshapes nutrition and metabolic health needs.
The UC Davis Innovation and Economic Development Office has launched the Aggie Venture Accelerator, an initiative designed to support early stage startups developing solutions at the intersection of life science, food and health.
The first Aggie Square Community Benefits Partnership Agreement (CBPA) Annual Progress Report has been released by UC Davis, the City of Sacramento and Wexford Science & Technology, documenting significant progress towards meeting many of the goals outlined in the CBPA.
UC Davis Health Ventures, part of the Innovation and Economic Development Office at UC Davis, today announced the appointment of Troels Adrian as Director of Industry Engagement.
Introducing the Food & Health Angels Network, a groundbreaking initiative launched to accelerate science-driven innovations in food and health, addressing the pressing issue of metabolic disease.
UC Davis showcased groundbreaking translational research and innovative biotech startups at the 8th Annual Biotech Innovation Gallery in San Francisco. Hosted by the UC Davis Innovation and Economic Development Office, the event brought in over 330 attendees to connect with and explore potential partnerships with researchers and startup founders, aligning with the J.P. Morgan Healthcare Conference.
The University of California, Davis, has awarded $100,000 through the autumn 2025 cohort of the Science Translation and Innovative Research (STAIR) Grant Program to help scientists advance innovative research with strong commercial potential.
At Venture Catalyst, part of the UC Davis Innovation and Economic Development Office, we're proud to support the translation of UC Davis research and technology into real-world applications by fostering the development of new ventures. Through strategic collaborations, training and mentorship programs, funding translational research, and proactive outreach, we foster the university’s entrepreneurial culture and ensure that the benefits of the UC Davis innovation ecosystem extend beyond the lab.
The Discovery Forum showcased UC Davis as a leader in GLP-1 and metabolic health innovation, bringing together researchers, industry experts, and investors to explore how metabolic hormones are reshaping health and nutrition. With cutting-edge research, world-class facilities, and a strong innovation ecosystem, the event was a reminder of UC Davis’ unique ability to translate metabolic science into real-world health and wellness solutions.
UC Davis Health Ventures, part of the Innovation and Economic Development Office (IEDO) at the University of California, Davis, today announced the first investment from its Investing in the Future of Medicine (IFM) Fund, backing Delix Therapeutics.
